Boston Scientific (NYSE:BSX) vs. GN Store Nord (OTCMKTS:GNNDY) Head to Head Review

GN Store Nord (OTCMKTS:GNNDY) and Boston Scientific (NYSE:BSX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

89.1% of Boston Scientific shares are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

GN Store Nord has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for GN Store Nord and Boston Scientific, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GN Store Nord	0	3	2	0	2.40
Boston Scientific	2	5	24	0	2.71

Boston Scientific has a consensus price target of $71.62, suggesting a potential upside of 52.86%. Given Boston Scientific’s stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific is more favorable than GN Store Nord.

Profitability

This table compares GN Store Nord and Boston Scientific’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GN Store Nord	-4.32%	-2.42%	-0.88%
Boston Scientific	17.50%	19.28%	10.89%

Valuation & Earnings

This table compares GN Store Nord and Boston Scientific”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GN Store Nord	$2.54 billion	0.90	$98.86 million	($1.80)	-25.14
Boston Scientific	$20.07 billion	3.38	$2.90 billion	$2.47	18.97

Boston Scientific has higher revenue and earnings than GN Store Nord. GN Store Nord is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Boston Scientific beats GN Store Nord on 13 of the 14 factors compared between the two stocks.

About GN Store Nord

GN Store Nord A/S provides hearing, audio, video, and gaming solutions in Denmark, rest of Europe, North America, and internationally. The company operates through GN Hearing and GN Audio segments. The GN Hearing segment produces and sells hearing instruments and products. The GN Audio segment supplies headsets, video cameras, and speakerphones for professional use and consumer products. It offers its products under the ReSound, Jabra, Beltone, Interton, Danavox, BlueParrott, FalCom, and SteelSeries brands. GN Store Nord A/S was founded in 1869 and is based in Ballerup, Denmark.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.